methods may have affected the type and severity of interference. We have reassessed the effect of CRF on serum fructosamine concentrations.
Patients and methods
Patients with CRF were drawn from the haemodialysis and peritoneal dialysis units of the Queen Elizabeth Hospital, Birmingham. Controls with normal renal function and plasma proteins were obtained from surgical clinics at the General Hospital, Birmingham. No patient had any evidence of diabetes. Samples from patients receiving haernodialysis were collected both before and after dialysis. Haemodialysis was performed using cuprophan dialysis membranes.
Blood was collected into glass tubes containing serum separation gel (Vacutainer, Becton Dickinson, New Jersey, USA). Creatinine, albumin and total protein were measured on a BM-Hitachi 717, using alkaline picrate reaction rate, bromocresol green reaction rate and biuret end point methods. Fructosamine was assayed by the method of Johnson et al.,' adapted for the Cobas MIRA and standardized against glycated polylysine (Roche Diagnostic Systems, Welwyn Garden City, UK). Pre-and post-dialysis samples from each patient were assayed within the same batch. The within-batch coefficient of variation is 2·3% at 247 /imol/L and 1·8% at 348 /imol/L. The FAR was expressed as fructosamine (umol/Lj/albumin (giL).
Analysis of variance with Tukey's test was used to compare differences between groups, and the t-test for paired samples (with the Shapiro-Wilk test for normality) to assess changes following haemodialysis. Multiple linear regression was used to assess the correlation between fructosamine and albumin, globulins and creatinine. Creatinine values were subjected to logarithmic transformation prior to analysis. Analyses were performed using the Minitab statistical package (Minitab Inc., PA, USA).
RESULTS
Thirty-nine patients with normal renal function, 34 with CRF treated by continuous ambulatory peritoneal dialysis (CAPD) and 34 treated by haemodialysis were studied. Mean serum concentrations of fructosamine, albumin, globulins and creatinine are shown in Table 1 . Regression analysis demonstrated a correlation between fructosamine and albumin in all groups (controls /=3'10, P=0'OO4; CAPD /=3'69, P=O·OOI; pre-haemodialysis, /=2'36, P=0'025; post-haemodialysis /=3'89, P=O·OOl). In haemodialysis patients, a significant correlation also existed between fructosamine and serum globulins, which before dialysis was stronger than that with albumin (controls t = O·84, P= 0'4; CAPD /= 1,89, P=0'07; pre-haemodialysis t = 3· 54, P= 0'001; post-haemodialysis /= 2· 56, P=0·016). There was no significant correlation with creatinine in any group (controls t = 1. 96, P=0·06; CAPD /=1,56, P>O'l; prehaemodialysis / = O· 48, P> 0·1; posthaemodialysis /= -0'56, P>O·l).
DISCUSSION
This study has confirmed the increased FAR reported previously in patients with CRF treated with either CAPD or HD. 5 Our results for fructosamine concentrations are also in keeping with this earlier work, given the greater reduction in albumin concentration which its authors reported in CAPD patients compared to controls.
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The association of fructosamine with globulin concentrations in haemodialysis patients may be due to several factors. The normal contribution from globulins would achieve greater prominence in the presence of a reduced concentration or increased turnover of albumin. Use of cuprophan dialysis membranes activates complement and coagulation, and induces platelet and granulocyte degranulation." Activation of complement and other enzymes could alter long-term susceptibility of proteins to glycation; while in the short term, release of intracellular proteins during dialysis may dilute the fructosamine reactivity of globulins.
The increased influence of globulins to fructosamine in haemodialysis patients contributes to the total fructosamine concentration and means that the times pan over which fructosamine gives information about diabetic control is altered from those with normal renal function. We believe the fructosamine assay would be unsuitable for monitoring of diabetic control in patients receiving haemodialysis.
